2 results
Approved WMOCompleted
To evaluate the efficacy and safety of T-817MA in patients with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease.
Approved WMORecruiting
TEMPO will directly compare i) conventional 2-step reduction with ii) gradual tapering in patients with remitted MDD who use either the antidepressant paroxetine (PAR) or venlafaxine (VLX). We will evaluate the number of patients that can…